APRE:NSD-Aprea Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.22

Change

-0.06 (-1.14)%

Market Cap

USD 0.11B

Volume

0.83M

Avg Analyst Target

USD 4.40 (-15.71%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-1.23 (-0.37%)

USD135.16B 39.56 31.39
BNTX BioNTech SE

+1.76 (+0.67%)

USD60.07B 13.82 10.18
REGN Regeneron Pharmaceuticals Inc

+8.63 (+1.59%)

USD58.13B 9.81 7.57
VRTX Vertex Pharmaceuticals Incorpo..

+4.61 (+2.55%)

USD47.16B 23.84 15.87
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+15.19 (+4.21%)

USD33.67B N/A N/A
SGEN Seagen Inc

+2.22 (+1.29%)

USD31.29B 53.66 40.74
GMAB Genmab A/S

+0.80 (+1.80%)

USD29.05B 74.96 8.12
ALNY Alnylam Pharmaceuticals Inc

+2.69 (+1.32%)

USD24.23B N/A N/A
RPRX Royalty Pharma plc

+0.68 (+1.84%)

USD23.31B 29.98 12.47

ETFs Containing APRE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.10% 70% C- 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.10% 70% C- 48% F
Trailing 12 Months  
Capital Gain -78.74% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.74% 2% F 1% F
Trailing 5 Years  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return 41.94% 69% D+ 59% F
Market Capitalization 0.11B 23% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.90 77% C+ 62% D-
Price / Cash Flow Ratio -2.68 23% F 59% F
EV/EBITDA 0.00 100% A+ 100% A+
Management Effectiveness  
Return on Equity -59.14% 47% F 25% F
Return on Invested Capital -52.38% 47% F 16% F
Return on Assets -31.29% 36% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.36 92% A- 89% B+
Short Percent 5.21% 49% F 33% F
Beta -0.12 95% A 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector